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Chinese patients with pain
A B S T R A C T
Objectives: The aim of this study is to evaluate the pharmacokinetic profile of oxycodone and three of its
metabolites, noroxycodone, oxymorphone and noroxymorphone after intravenous administration in
Chinese patients with pain.
Methods: Forty-two subjects were assigned to receive intravenous administration of oxycodone
hydrochloride of 2.5, 5 or 10 mg. Plasma and urine samples were collected for up to 24 h after
intravenous administration of oxycodone hydrochloride.
Results: Pharmacokinetic parameters showed that mean values of Cmax, AUC0–t and AUC0–1 of
oxycodone were dose dependent, whereas Tmax and t1/2 were not. The mean AUC0–t ratio of
noroxycodone to oxycodone ranged from 0.35 to 0.42 over three doses, and those of noroxymorphone, or
oxymorphone, to oxycodone were ranging of 0.06–0.08 and 0.007–0.008, respectively. Oxycodone and
its three metabolites were excreted from urine. Approximately 10% of unchanged oxycodone was
recovered in 24 h. Most adverse events (AEs) reported were mild to moderate. The frequently occurred
AEs were dizziness, nausea, vomiting, drowsiness and fatigue. No dose-related AEs were found.
Conclusion: Our pharmacokinetics of oxycodone injection in Chinese patients with pain strongly support
continued development of oxycodone as an effective analgesic drug in China.
 2014 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp.
z o.o. All rights reserved.
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Oxycodone, a semi-synthetic opioid analog, is widely used to
treat the moderate or severe degrees of cancer pain [11],
postoperative pain [18] and neuropathic pain [20]. Oxycodone is
a m- and k-opioid receptor agonist and has similar pharmacologic
effects with morphine [6,10]. In oral administration, oxycodone
has shown a bioactivity 1.5- to 2-folds higher than that of
morphine [2], but the side effects such as nausea and hallucina-
tions less than those of morphine [7].
Pharmacokinetic studies indicated that after intravenous ad-
ministration, oxycodone shows a mean terminal half-life (t1/2) of
3.7–5.5 h [12,18], which is comparable with that of oral adminis-
tration (3.5–5.1 h) [13,19]. The mean dose-normalized area under
the concentration–time curve AUC is also similar to that after
receiving oral oxycodone tablets, whereas the latter can be affected
by food and general anesthesia [6]. Oxycodone is extensively* Corresponding author.
E-mail address: YLS307@126.com (Z.-Y. Liu).
1 These authors contributed equally to this work.
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http://dx.doi.org/10.1016/j.pharep.2013.08.012metabolized in liver. The major fraction of oxycodone is N-
demethylated by CYP3A4 to noroxycodone. A smaller fraction of
oxycodone is O-demethylated to oxymorphone by CYP2D6. Further
oxidation of these metabolites yields noroxymorphone. Some other
reductive and conjugated glucuronides are also discovered [15].
Among these metabolites, noroxycodone has weak affinity to m-
opioid receptor [3], whereas oxymorphone has analgesic potency
approximately 10-folds more than that of morphine [1]. These
metabolites are excreted from urine. Most of oxycodone and
noroxycodone are excreted as their free forms, whereas oxymor-
ophone is mainly excreted in a conjugated form [19].
Oxycodone entered into clinical practice since 1917, and to
date, various formulations had been developed, including oral
immediate- and controlled-release formulations, intravenous
ampouls as well as combination formulations, for example,
together with paracetamol [14]. In China, oxycodone is only
available in the form of oral controlled-release tablets. Although
oral administration is the most preferred route by patients,
alternative route is considerable when patients have gastrointes-
tinal disease or difficulty in swallowing, or when patients have
great and acute pain or poor pain control. The intravenous
administration is a commonly used as an alternative for theseSciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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intravenous administration of oxycodone reported in Chinese
people. The aim of this study is to determine the pharmacokinetics
of oxycodone and three of its metabolites after intravenous
administration to Chinese patients with pain.
Materials and methods
Ethics
This study was conducted in accordance with the Declaration of
Helsinki [21] and the requirements described in Chinese Good
Clinical Practice. The protocol was approved by the Ethic
Committee of affiliated Hospital of the Academy of Military
Medical Sciences. All the participants provided written informed
consent and agreed to the study protocol.
Study participants
The subjects were aged 30–60 years old with a body mass index
(BMI) of 19–24 kg/m2 and a minimum weight of 45 kg. They were
breast or colorectal cancer patients with pain and rheumatic
patients with chronic musculoskeletal pain. All subjects had the
Karnofsky Performance scale score greater than 70 and their survival
periods were expected longer than three months. Participants were
inclusive if they had not taken opioid medicines within the three
months prior to study. In addition, all the participants were required
to have hepatic function with ALT or AST level less than 2-folds of
normal values and were required to have renal function with the
value of total bilirubin, blood urea nitrogen and creatinine level less
than 1.25-folds of upper limit of normal value. They were also
required to have normal electrocardiogram without clinically
significant abnormalities. The patients were excluded if they had
hypersensitivity to opioid analgesic agents, had a history of drug or
alcohol abuse, had treatment with daily prescribed medications on
opioids, or had treatment with monoamine oxidase inhibitors for
two weeks before the study initiation day. The subjects were
excluded if they had participated in other drug trials within previous
two months, had given blood donations of 400 mL or more within
three months or 200 mL or more within one month previously.
Female subjects were excluded if they were pregnant. In addition,
subjects were required to have a negative urine test for drugs such as
opiates, barbiturates, amphetamine, cocaine, methadone, benzo-
diazepines and cannabinoids. Eligible patients signed an informed
consent and were given detailed instruction of the study.
Study design and treatments
This was a single dose and parallel-group trial in Chinese
patients with pain. The subjects were divided into three groups,
respectively named as A, B, C. The doses of administration of
oxycodone in the three groups were 2.5 mg, 5 mg and 10 mg,
respectively. The oxycodone hydrochloride injection was diluted in
0.9% sodium chloride to 10 mL. Then the solution was infused over
two minutes into the forearm of the patient. For safety, the dose of
2.5 mg oxycodone was administrated firstly. After the study of
2.5 mg dose group completed, the dose of 5 mg oxycodone was
then given. The dose of 10 mg oxycodone was administrated after
the end of the study of 5 mg dose group. About 4 h after drug
administration, standard meals were offered and until 24 h after
administration, alcohol and coffee were prohibited.
Pharmacokinetic sampling
About 4 mL of blood samples were collected from an indwelling
venous catheter into heparinized vacutainers prior to dosing and0 min, 2 min, 5 min, 10 min, 15 min, 30 min, 45 min, 1 h, 1.5 h, 2 h,
3 h, 4 h, 6 h, 8 h, 12 h, 24 h after drug administration. Samples were
inverted slightly and then centrifuged at 1500  g for 10 min at
4 8C. The resulting plasma was transferred to screw-caped tubes.
Within 60 min of collection, plasma samples were frozen at 20 8C
and kept for analysis.
Urine samples were obtained before dosing and at pooled
intervals of 0–2, 2–4, 4–8, 8–12, 12–24 h after drug administration.
Urine sample in each interval was mixed, and the total volume was
recorded. Aliquots of 5 mL was collected into containers and stored
at 20 8C.
Bioanalytical methods
Plasma concentrations of oxycodone, noroxycodone, oxy-
morphone and noroxymorphone were determined with liquid
chromatography with tandem mass spectrometric (LC–MS/MS)
method. The plasma samples were prepared by the reported
method in our previous research with minor modification [5].
The samples were extracted with Empore MPC-SD, high
performance extraction disk plate (3M Company, USA). After
been activated, the extraction disk plate was loaded with
2  300 mL of plasma spiked with IS and 0.1% trifluoroacetic
acid, followed by a serial of elution and extraction. The final
elution was evaporated to dryness and then reconstituted with
200 mL of acetonitrile with 0.1% formic acid (0.2% formic acid
solution and 20 mM ammonium formate, 9:1, v:v). An aliquot of
50 mL of dissolved residue was applied to LC–MS/MS for
analysis. HPLC separation was achieved with an Agilent 1200
LC system. Chromatography was performed on Kromasil 100-
5SIL-Dimensions C18 column (2.1 mm  100 mm, 5.0 mm,
Thermo Hypersil-Keystone, USA) with 0.75 mL min1 flow rate.
The mobile phase consisted of (A) 0.2% formic acid solution
containing 20 mM ammonium formate, (B) acetonitrile solution
containing 0.1% formic acid. The elution procedure was as
follows: 0–0.3 min 95% (B); 0.3–1.0 min, 95–88% (B); 1.0–
3.6 min 88% (B); 3.6–3.7 min, 88–95% (B); 3.7–6.5 min, 95% (B).
Mass spectrometry analysis was operated with an API 3000 MS/
MS system (Applied Biosystems, USA) equipped with electro-
spray ionization source (ESI). The scan was operated in positive
and multiple reaction monitoring (MRM) mode. The parameters
of scan were as follows: 2000 V of spray voltage; 540 8C of ion
source temperature; 7 psi of GS1 pressure and 12 psi of
GS2 pressure; 38 V of collision energy for oxycodone, 40 V
for noroxycodone, 39 V for oxymorphone and 40 V for norox-
ymorphone. Quantification was performed based on the transi-
tions of m/z 316.2 ! 241.1, 302.2 ! 227.1, 302.2 ! 227.1,
288.1 ! 213.0, 319.2 ! 244.0, 305.2 ! 230.2, 305.2 ! 230.2
and 293.1 ! 216.0 for oxycodone, noroxycodone, oxymorphone,
noroxymorphone, oxycodone-D3, noroxycodone-D3, oxymor-
phone-D3, and noroxymorphone-D9, respectively. The
analytical range of the assay for oxycodone, noroxycodone,
oxymorphone and noroxymorphone were all 0.1–50.0 ng/mL.
The lower limit of quantitation (LLOQ) of all of the four
compounds was 0.1 ng/mL.
Urine analysis was similar with plasma. Aliquots of 250 mL of
mixture containing 50 mL of urine sample, 100 mL of IS solution
and 100 mL of 0.1% trifluoroacetic acid was applied to extraction
disk plate, which had been conditioned in advance. The following
process was the same as that of plasma. The calibration curve of
urine samples was ranged from 5.0 to 500.0 ng/mL for oxycodone
and noroxycodone, 1.0 to 100.0 ng/mL for oxymorphone, and 2.5
to 250.0 ng/mL for noroxymorphone, respectively. The LLOQ
of oxycodone, noroxycodone, oxymorphone and noroxymor-
phone were 5.0 ng/mL, 5.0 ng/mL, 1.0 ng/mL and 2.5 ng/mL,
respectively.
Table 2
Demographics and characteristics of subjects included into pharmacokinetic
analyses.
Characteristics Study groups included into pharmacokinetic
analysis
2.5 mg dose
group (n = 9)
5 mg dose
group (n = 11)
10 mg dose
group (n = 12)
Gender, n (%)
Male 5 (56) 6 (55) 9 (75)
Female 4(44) 5 (45) 3 (25)
Age, yrs
Mean (SD) 45.2 (9.7) 41.0 (9.8) 38.80 (6.3)
Range 31–60 30–59 30–51
Race, n% Han (100) Han (100) Han (100)
Height, m
Mean (SD) 1.65 (0.08) 1.63 (0.09) 1.64 (0.06)
Range 1.56–1.81 1.46–1.79 1.54–1.74
Weight, kg
Mean (SD) 61.3 (8.3) 59.7 (4.9) 62.2 (4.7)
Range 49.5–72.0 50–69 55–70
BMI, kg m2
Mean (SD) 20.5 (1.6) 21.7 (1. 8) 22.5 (0.9)
Range 19.1–25.9 19.3–26.1 20.8–24.6
Type of pain, n (%)
Cancer pain 9 (100) 5 (45) 3 (25)
Musculoskeletal pain 0 6 (55) 9 (75)
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Vital signs including blood pressure, pulse rate, respiratory rate
and temperature were monitored before the drug administration,
during the trials at 2, 4, 6 and 24 h after drug administration and at
the end of study. Physical examination and ECG were also
performed before the drug administration and at 24 h after drug
administration. Hematology, serum chemistry and urinalysis test
were performed before the drug administration and at the end of
study. Adverse events (AEs) were recorded throughout the trial.
The principle investigators assessed the severity of AEs and the
correlations with the various kinds of treatments.
Statistics
The maximum plasma drug concentration (Cmax) and the time
needed to reach the maximum concentration (Tmax) were obtained
from direct observation of the data. The area under the
concentration–time curve (AUC) was calculated both from time
zero to infinity (AUC0–1) and from time zero to the last measurable
concentration (AUC0–t). The concentration–time data were ana-
lyzed by non-compartmental method in WinNonlin professional
Version 6.1 (Pharsight Corporation). The clearance of metabolite
(CLm) was calculated from CLm = CL  % dose  102, where CL is
the oxycodone clearance and % dose is the percentage of the dose of
individual metabolites excreted in urine over 0–24 h. The AUC0–t
ratio of metabolite to parent drug was calculated to assess the
relative amount of each metabolite in circulation. The pharmaco-
kinetic parameters were analyzed for differences between treat-
ments using an analysis of variance (ANOVA) model with single
factor. Statistical significance was set at p < 0.05.
Results
Experimental design
Forty-four subjects were enrolled in the study. Two subjects
were excluded because of unqualified physical examination before
drug dose. The rest of forty-two subjects all completed the study
and were included in the safety assessment. Among the forty-two
subjects, ten subjects were excluded from pharmacokinetic
analysis because of blood sampling in the forearm of receiving
drug infusion. The demographics and characteristics of subjects
included in the safety assessment and included in pharmacokinetic
analysis were separately shown in Tables 1 and 2.Table 1
Demographics and characteristics of subjects included into the safety assessment.





Mean (SD) 41.80 (10.21)
Range 23–60
Race, n% Han (100)
Height, m
Mean (SD) 1.63 (0.08)
Range 1.46–1.81
Weight, kg
Mean (SD) 61.23 (6.75)
Range 49.5–81
BMI, kg m2
Mean (SD) 23.11 (2.32)
Range 19.10–28.55
Type of pain, n (%)
Cancer pain 27 (64)
Musculoskeletal pain 15 (36)Pharmacokinetics
The mean plasma concentration of oxycodone and three of its
metabolites after intravenous administration of 2.5, 5 or 10 mg of
oxycodone hydrochloride to patients with pain were shown in
Fig. 1. Table 3 presents a summary of pharmacokinetic parameters.
The pharmacokinetics was found to be linear over three doses.
Mean values for Cmax, AUC0–t and AUC0–1 of oxycodone,
noroxycodone, oxymorphone and noroxymorphone increased in
a dose-proportional manner. Tmax values of oxycodone and its
three metabolites were independent of doses. Although the Tmax
values of the four compounds in 2.5 mg of dose group were shown
higher than those of other two groups, no statistical difference was
observed.
The mean t1/2 of oxycodone, noroxycodone, oxymorphone and
noroxymorphone was also independent of doses. The t1/2 values of
oxycodone and noroxycodone in 2.5 mg of dose group were higher
than those of other two groups. However, no significant difference
was observed. Oxymorphone t1/2 in the 2.5 mg dose group was not
calculated because of frequent concentrations below the limit of the
assay. In addition, the values of t1/2 of three metabolites were all
longer than that of oxycodone. Noroxymorphone had the longest t1/2
which was ranging from 11.98 to 13.88 h over the three doses.
The plasma concentrations of the three metabolites were all
lower than those of parent drug. Noroxycodone was the most
abundant metabolite, which had a mean AUC ratio of ranging from
0.34 to 0.42 over the three doses. Noroxymorphone and
oxymorphone had lower concentrations with a mean AUC ratio
ranged from 0.06 to 0.08 and 0.007 to 0.008, respectively, among
the three dose groups.
The CL of oxycodone among the three dose groups was
37.57  15.85, 42.42  10.44, 44.92  9.4 L/h, respectively, which
was not significantly different. The CLm value was also comparable
over the three doses. Cumulative urinary excretion was measured
over a 24-h period. Approximately 10% of unchanged oxycodone was
recovered.
Safety results
A total of 58 AEs were reported by 24 (57%) of the 42 subjects in
this study. The five most common AEs were dizziness (18 subjects,
Fig. 1. Mean plasma concentration–time profile of oxycodone (A), noroxycodone (B), oxymorphone (C) and noroxymorphone (D) after intravenous administration of 2.5, 5 or
10 mg of oxycodone to Chinese patient with pain.
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drowsiness (5 subjects, 20.8%), and fatigue (5 subjects, 20.8%). One
subject had severe dry mouth and was not given treatment. Two
subjects had moderate nauseas and vomiting, with the treatment
of intramuscular administration of metoclopramide and diphen-
hydramine. No other medications were administrated during the
study. The majority of AEs was mild and none of these events was
dose related. These events were consistent with those expected
from the administration of opioid analgesics. No death and no
serious events were reported. No clinically significant changes of
vital sign and laboratory examination were observed during this
study.
Discussion
Since it was introduced to clinical practice in the early 20th of
century, oxycodone has been widely used in many countries. Many
studies were carried out to investigate the pharmacological
characteristics of oxycodone. However, there are no reported
studies about pharmacokinetic profile of oxycodone in Chinese
people. The purpose of this study was to evaluate the pharmaco-
kinetic profile of oxycodone after the administration of oxycodone
hydrochloride injection in Chinese patients with pain. It was the
first description of pharmacokinetic characteristics of oxycodone
in Chinese patients.
In this study, oxycodone exhibited linear dynamic character-
istics. Increasing doses of oxycodone resulted in proportional
increases of Cmax and AUC, while Tmax and t1/2 was unchanged.
These pharmacokinetic parameters of oxycodone were all shownin close agreement with those reported from other studies given
intravenous oxycodone in cancer patients [11,13]. The CL value of
oxycodone (42.42 L/h) at the 5 mg dose group was also comparable
with that (46.8 L/h) in surgical patients [18]. The amount of
recovery of unchanged oxycodone from urine in 24 h was
approximately 10% which was similar with that (11%) reported
previously [8].
It has been known that oxycodone can be metabolized to
produce three main metabolites, noroxycodone, oxymorphone and
noroxymorphon [9]. Because of the minor amount of metabolites
in circulation, few studies have been reported about the
pharmacokinetic profile of the three metabolites. In this study,
these metabolites were analyzed by a sensitive LC–MS/MS method
with a lower LLOQ (0.1 ng/mL) than that (0.25 ng/mL) reported by
Neuvonen and Neuvonen [16]. Results showed that the plasma
concentrations of the three metabolites increased in proportional
to dose. The pharmacokinetics of these metabolites was linear in
the dose range of 2.5–10 mg of oxycodone. The mean recovery of
these metabolites from urine, as percent of dose, was similar over
three doses. Approximately 25% of dose of oxycodone including
unchanged parent drug and three free metabolites were recovered.
It was supported by previous studies which showed that there
were fractions of the four compounds excreted as conjugated
glucuronides [8,9].
In addition, there are large inter-individual variations observed
in t1/2, especially in 2.5 mg dose group. The oxycodone t1/2 in the
2.5 mg dose group was 8.93  8.34 h, which was higher than those
of the other two groups. It was a result of one subject with t1/2 value of
30.87 h. Similarly, noroxycodone t1/2 (17.48  17.88 h) in the 2.5 mg
Table 3
Summary of pharmacokinetic parameters for oxycodone and three of its metabolites after intravenous administration of 2.5, 5 and 10 mg of oxycodone in Chinese patients
with pain.
Pharmacokinetic parameters Intravenous administration of oxycodone
2.5 mg (n = 9) 5 mg (n = 11) 10 mg (n = 12)
Cmax, ng/mL
Oxycodonea,b,c 65.69  51.38 147.74  77.31 279.68  158.54
Noroxycodonea,b,c 1.68  0.76 3.22  0.94 7.88  1.29
Oxymorphonec – 0.26  0.1 (n = 10) 0.48  0.18 (n = 11)
Noroxymorphoneb,c 0.37  0.26 (n = 5) 0.60  0.30 1.26  0.53
Tmax, h
Oxycodone 0.14  0.33 0.04  0.01 0.05  0.03
Noroxycodone 3.39  2.18 1.15  1.22 1.45  1.39 h
Oxymorphone – 0.40  0.29 (n = 10) 0.78  1.74 (n = 11)
Noroxymorphone 7.10  7.82 (n = 7) 3.78  3.07 2.16  2.00
AUC0–t, h ng/mL
Oxycodonea,b,c 67.56  22.56 117.29  25.34 227.62  45.16
Noroxycodone 23.04  10.10 40.31  17.09 91.16  16.78
Oxymorphonec – 0.75  0.53 (n = 10) 1.66  1.07 (n = 11)
Noroxymorphoneb,c 4.92  3.66 (n = 7) 7.34  3.88 17.91  5.70
AUC0–1, h ng/mL
Oxycodonea,b,c 83.75  54.49 124.59  30.5 231.32  46.51
Noroxycodonea,b,c 40.60  28.08 51.08  34.70 102.06  21.49
Oxymorphoneb – 2.52  2.15 3.04  1.0
Noxymorphone 9.07  5.79 (n = 5) 10.47  3.25 30.64  32.38
t1/2, h
Oxycodone 8.93  8.34 4.59  0.8 4.17  0.45
Noroxycodoneb 17.48  17.88 8.08  4.59 6.90  1.24
Oxymorphone – 7.64  6.29 (n = 10) 6.28  2.31 (n = 9)
Noroxymorphone 13.88  10.35 (n = 5) 11.98  13.22 (n = 10) 13.78  11.44
CL, L/h
Oxycodone 37.57  15.85 42.42  10.44 44.92  9.4
CLm, L/h
Noroxycodone 4.94  2.52 4.97  3.14 6.32  3.26
Oxymorphone – 0.15  0.09 0.11  0.05 (n = 11)
Noroxymorphone 0.92  0.68 1.29  0.84 (n = 10) 1.33  0.74
V, L/kg
Oxycodoneb 6.29  2.75 4.61  0.91 4.34  0.94
Noroxycodone 1.55  1.28 1.25  1.89 1.03  0.52
Oxymorphone – 0.02  0.02 (n = 10) 0.02  0.01 (n = 9)
Noroxymorphone 0.36  0.23 (n = 5) 0.29  0.19 (n = 10) 0.39  0.29
AUC0–t ratio
Noroxycodone/oxycodone 0.35  0.14 0.36  0.18 0.42  0.12
Oxymorphone/oxycodone – 0.007  0.005 0.008  0.005
Noroxymorphone/oxycodone 0.08  0.06 0.06  0.03 0.08  0.02
Excretion in the urine, mg (%)
Oxycodone 263.91  128.94 (10.56  5.16) 485.23  214.79 (9.70  4.30) 978.18  502.18 (9.78  5.02)
Noroxycodone 332.03  121.78 (13.28  4.87) 588.45  313.87 (11.77  6.28) 1366.56  524.52 (13.67  5.25)
Oxymorphone 6.70  3.89 (0.27  0.16) 18.35  13.54 (0.37  0.27) (0.23  0.10)
Noroxymorphone 57.14  27.91 (2.29  1.12) 156.31  115.57 (3.13  2.31) 288.48  126.03 (2.88  1.26)
Note: –, the concentration of only one subject could be measured.
a Significant difference between IV oxycodone 2.5 mg and 5 mg dose.
b Significant difference between IV oxycodone 2.5 mg and 10 mg dose.
c Significant difference between IV oxycodone 5 mg and 10 mg dose.
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attributed to significantly high t1/2 values of 40.07 h and 55.93 h from
two subjects. Oxycodone is mainly eliminated by metabolism, which
is believed to occur mainly in liver [12]. However, among the enzymes
involving metabolism of oxycodone, CYP3A4 expression exists 50-
fold inter-individual difference [4] and CYP2D6 expression is
regulated by four different genotypes [22], which maybe result in
large variations of t1/2 in our study.
The Cmax value of oxycodone in the 5 mg dose group was higher
(147.74 ng/mL) than that (59.5 ng/mL) of reported by Leow et al.
[12], which was due to the different method of drug delivery and
different time of blood sampling. Leow et al. reported that the
whole injection of oxycodone hydrochloride solution completedover 0.5–5 min and blood sampling began at the 2 min after
administration. However, in our study, the 10 mL of dissolved
oxycodone injection was infused within 2 min and blood samples
were collected immediately after dose. The different operation
accounted for the difference of Cmax. Although the Cmax showed a
higher value, AUC of oxycodone in the 5 mg dose group was not
different with that of previous report [13]. Furthermore, analysis of
safety results showed that most of adverse events (for example,
dizziness, nausea, vomiting and drowsiness) occurred in our study
was mild to moderate, which was consistent with those reported in
other studies [11,17].
In our study, the recruited patients were drawn from applicable
people of oxycodone. The participants were all patients with
G.-T. Hao et al. / Pharmacological Reports 66 (2014) 153–158158cancer pain or rheumatic patients with chronic musculoskeletal
pain. The number and percentage with musculoskeletal pain and
cancer pain in each study group were not very similar, which was a
limitation of our study. However, during the study, we found that
the treatments were all well tolerated and the incidence of side
effects had not significant difference between cancer patients and
rheumatic patients. In addition, except for two subjects in 10 mg
dose group with moderate nausea and vomiting, others all showed
mild side effects. About the pharmacokinetic results, previous
researches [23] had indicated that the pharmacokinetics of
oxycodone could be influenced by sex, age, liver and renal
function, etc. Kirvela et al. [8] reported that the elimination of
oxycodone was impaired in uremic patients. Tallgren et al. [24]
also reported that oxycodone clearance decreased in severe
hepatic failure patients. In our study, all the participants had
hepatic function with ALT or AST level less than 2-folds of normal
values and had renal function with creatinine level less than 1.25-
folds of upper limit of normal value, which indicated that the liver
and renal function of our patients could not affect the metabolism
and clearance of oxycodone. The consistent results compared to
previous research could also support it.
Oxycodone was an analgesic medicine which was widely used
in patients with cancer pain or chronic non-cancer pain. Further
research of large numbers of patients with cancer pain or chronic
non-cancer pain was needed. Our study was the fist research of
pharmacokinetic characteristics of oxycodone in Chinese patients.
The pharmacokinetics of oxycodone injection in Chinese patients
with pain strongly support continued development of oxycodone
as an effective analgesic drug in China.
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